Participating in the chat will be two diabetes experts and co-authors of a new American Diabetes Association position statement on the care of people with type 1 diabetes.
The Bamberg Diabetes Transitional Care Study will utilize cutting-edge iPad technology to explore the impact and feasibility of different diabetes interventions for patients transitioning from the hospital to home.
John B. Buse, MD, PhD, chief of the division of endocrinology and director of the Diabetes Care Center, has been ranked as one of the world’s foremost experts in type 2 diabetes based on an analysis of publications in the National Library of Medicine’s MEDLINE database.
The newest American Diabetes Association treatment guidelines for the disease are in place at UNC Medical Center.
Collaboration will leverage big data to help providers engage patients to manage diabetes, improve health
The ENDO Trial is currently enrolling adults between the ages of 21 and 65 who have uncontrolled type 2 diabetes and are obese.
Beginning recruitment in June, the project is called the Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness (GRADE) Study. UNC will enroll patients at locations in Durham and Greensboro, N.C.
The Patient-Centered Outcomes Research Institute awards UNC School of Medicine researchers more than $2 million to study glucose monitoring in non-insulin treated patients living with type 2 diabetes.
An investigation into diabetes-related outcomes in a rat model, with senior author William Valdar, PhD, assistant professor of genetics at UNC, and first author Leah Solberg Woods, PhD, from the Medical College of Wisconsin, has made the editor's pick in this month's Physiological Genomics, a journal of the American Physiological Society.
The 2013 Harold Hamm International Prize for Biomedical Research in Diabetes encourages research focused on progress toward a cure.
Daily injections of liraglutide were slightly more effective than weekly injections of exenatide in lowering blood sugar and promoting weight loss. However, patients had fewer negative side effects on exenatide once weekly.
Overall, eleven specialties at UNC Hospitals were recognized as nationally ranked or high performing by U.S. News & World Report in its annual "America's Best Hospitals" issue.
Scientists at the University of North Carolina School of Medicine have used injections of antibodies to rapidly reverse the onset of Type I diabetes in mice genetically bred to develop the disease.
Dr. John Buse, director of the UNC Diabetes Care Center and chair of the National Diabetes Education Program, will host a live Facebook chat on diabetes management and prevention on Tuesday, May 22.
The goal of the study is to identify genetic variations that may help predict the response to various treatment options for type 2 diabetes to reduce cardiovascular disease.
First clinic to receive NCQA Diabetes Recognition Program recertification via new electronic submission
The UNC Internal Medicine Clinic achieved recertification for the National Committee for Quality Assurance (NCQA) Diabetes Recognition Program November 2011-2014.
New research from the University of North Carolina at Chapel Hill School of Medicine adds clarity to the connection. The study published on-line April 10th in the journal Nature Immunology finds that saturated fatty acids but not the unsaturated type can activate immune cells to produce an inflammatory protein, called interleukin-1beta.
A new study finds that combining the newer diabetes drug exenatide with insulin provides better blood sugar control in patients with type 2 diabetes than insulin alone and helps promote weight loss.
When asked his thoughts about the Avandia controversy, Dr. John Buse, director of the UNC Diabetes Care Center and past president of the American Diabetes Association, had this to say…
The Taking Control of Your Diabetes Conference and Health Fair will take place on May 22.